The Centers for Medicare & Medicaid Services granted reimbursement for Illumina’s TruSight Oncology Comprehensive assay at $2,989.55 per test under PLA code 0543U, effective Jan. 1, 2026. The CMS decision follows the assay’s FDA approval and covers comprehensive genomic profiling for solid tumors, including markers tied to approved targeted therapies. Illumina said the reimbursement removes a major barrier to clinical uptake and could accelerate adoption of tumor‑agnostic testing in routine oncology care.